Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPRI-424 versus placebo for hirsutism in women with polycystic ovary syndrome
ISRCTN76318215Phase 3Completed
- Sponsor
- Chemo
- Start
- Nov 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of dienogest and ethinyl estradiol in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Chemo. Primary endpoint: Change in hirsutism severity by modified Ferriman-Gallwey score. Started Nov 2021; status: completed.
02
Drugs
dienogestethinyl estradiol
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ISRCTN76318215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN76318215.